CircEXOC6B Suppresses the Proliferation and Motility and Sensitizes Ovarian Cancer Cells to Paclitaxel Through miR-376c-3p/FOXO3 Axis

Zheng, Yinjian; Li, Zhen; Yang, Shiying; Wang, Yue; Luan, Zhaohui

doi:10.1089/cbr.2020.3739

Cited by 26 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although strategies for OC therapy have improved in recent years, chemoresistance remains a major barrier to the effectiveness of OC treatments (Gottesman, 2002). Convincing evidence has verified the involvement of circRNAs in the chemosensitivity of human cancers, including OC (Guo et al, 2020; Li et al, 2020; Zheng et al, 2020). In the current report, we selected circATL2 as our study object, which was upregulated in PTX‐resistant OC patients through microarray assay (Xia et al, 2020).…”

Section: Resultsmentioning

confidence: 92%

CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR‐506‐3p/NFIB axis

Ying

Zhao

et al. 2021

Drug Development Research

View full text Add to dashboard Cite

Circular RNAs (circRNAs) play vital regulatory roles in the development of ovarian cancer (OC). However, the functions of circRNA Atlastin GTPase 2 (circATL2) in paclitaxel (PTX) resistance of OC are still unclear. As a result, circATL2 was upregulated in PTX‐resistant OC tissues and cells. CircATL2 knockdown reduced IC50 of PTX, inhibited colony formation ability and promoted cell cycle arrest and apoptosis in PTX‐resistant OC cells. Silencing of circATL2 restrained PTX resistance in vivo. Furthermore, miR‐506‐3p could be targeted by circATL2 and miR‐506‐3p inhibition reversed the impacts of circATL2 knockdown on PTX resistance and cell progression in PTX‐resistant OC cells. NFIB was identified as the target of miR‐506‐3p. MiR‐506‐3p overexpression suppressed PTX resistance and malignant behaviors of PTX‐resistant OC cells, with NFIB elevation rescued the impacts. To summarize, circATL2 promoted the resistance of OC to PTX by sponging miR‐506‐3p to upregulate NFIB expression, providing a new sight in chemoresistance of OC.

show abstract

Section: Resultsmentioning

confidence: 92%

CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR‐506‐3p/NFIB axis

Ying

Zhao

et al. 2021

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…circ_0006404 and circ_0000735 were reported to regulate the response of ovarian cancer to docetaxel by regulating p-Gp levels as a miRNA sponge [18]. In addition, circTNPO3 and circEXOC6B were also found to be concerned with the chemoresistance of ovarian cancer [19,20]. In this study, we determined circSETDB1, which was prominently upregulated in Ptx-resistant tissues and cells of ovarian cancer, could accelerate the ovarian cancer cells sensibility to Ptx in vitro and in vivo through knockdown.…”

Section: Discussionmentioning

confidence: 99%

CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression

Huang

Chen

et al. 2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

Ovarian cancer is a gynecological tumor with a poor prognosis. The chemotherapy failure and recurrence induced by paclitaxel (Ptx) resistance are the main reason for the failure of ovarian cancer treatment. In this study, we aimed to explore the role of circular RNA (circRNA) in the regulation of Ptx resistance in ovarian cancer. Quantitative reverse transcription PCR was performed to detect the expression of circRNA SET domain bifurcated histone lysine methyltransferase 1 (circSETDB1), microRNA (miR)-508-3p and ATP-binding cassette subfamily C member 1 (ABCC1) mRNA. The effects of circSETDB1 on Ptx resistance were explored by cell counting kit-8, 5-ethynyl-2′-deoxyuridine, and flow cytometry experiments in vitro. The protein level was assessed by western blot. Dual-luciferase reporter and RNA pull-down assays were carried out to confirm the interactions among circSETDB1, miR-508-3p, and ABCC1. Xenograft tumor experiment was performed to investigate the effect of circSETDB1 on Ptx resistance in vivo. CircSETDB1 was highly expressed in Ptx-resistant ovarian cancer. CircSETDB1 knockdown inhibited cell proliferation viability, half maximal inhibitory concentration value of Ptx, cell cycle progression, and induced cell apoptosis in Ptx-resistant ovarian cancer cells. miR-508-3p was a target of circSETDB1, and inhibition of miR-508-3p overturned the effects of circSETDB1 knockdown on the Ptx resistance of ovarian cancer cells. miR-508-5p could bind to ABCC1. Overexpression of ABCC1 reversed the effects of circSETDB1 knockdown on the Ptx resistance of ovarian cancer cells. CircSETDB1 knockdown also enhanced Ptx sensitivity in vivo. In conclusion, circSETDB1 regulated Ptx resistance of ovarian cancer by targeting miR-508-3p/ABCC1 axis.

show abstract

“…Therefore, circRNAs have the chance to be excellent biomarkers for BC diagnosis, prognosis and drug resistance assessment 3,33,48,49 . Some studies have concentrated on the effects of circRNAs on chemoresistance in breast, cervical 50 , colorectal 51,52 , gastric 53,54 , lung 55 , oral 56 , ovarian 57 , pancreatic 58 and prostate 59 cancers. In this study, we collected relevant articles before 25 October 2021 and conducted a systematic review and meta-analysis, hoping to find clues about the value of circRNAs as biomarkers for BC prognosis.…”

Section: Discussionmentioning

confidence: 99%

Current evidence on circRNAs as potential theranostic markers for detecting chemoresistance in breast cancer: a systematic review and meta‑analysis

Zhu

Jiang

Xie

et al. 2022

Sci Rep

View full text Add to dashboard Cite

This study assessed the value of circRNAs (circular RNAs) as prognostic markers in BC (breast cancer). We searched pertinent studies on the PubMed, Embase, and Web of Science online databases published according to PRISMA guidelines. A random-effects model for meta-analysis was used to assess the combined effect size of the HRs (hazard ratios) of the included studies. The heterogeneity test used Cochran's Q-test and I2 statistics. Thirty of the 520 trials retrieved were included in the systematic review. A total of 11 chemotherapeutic agents were used in the included studies. A total of 30 studies on 30 circRNAs were included in the systematic review. Of the 30 relevant circRNAs, 28 were upregulated and two were downregulated in breast cancer versus normal samples, and both were associated with increased drug resistance. Nine of 30 studies were used for the meta-analysis. The results of the meta-analysis showed that the groups with circRNA upregulation and circRNA downregulation showed the same prognostic risk (HR = 1.37, 95% Cl: 0.80–2.36, I2 = 63.7%). The results of subgroup analysis showed that both upregulated circRNAs (HR = 2.24, 95% Cl: 1.34–3.75, I2 = 0%) and downregulated circRNAs (HR = 0.61, 95% Cl: 0.45–0.83, I2 = 0%) were associated with poor BC prognosis. Collectively, the results of all relevant articles collected indicated that circRNAs showed good potential as possible clinical biomarkers of chemoresistance in BC patients.

show abstract

CircEXOC6B Suppresses the Proliferation and Motility and Sensitizes Ovarian Cancer Cells to Paclitaxel Through miR-376c-3p/FOXO3 Axis

Cited by 26 publications

References 33 publications

CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR‐506‐3p/NFIB axis

CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR‐506‐3p/NFIB axis

CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression

Current evidence on circRNAs as potential theranostic markers for detecting chemoresistance in breast cancer: a systematic review and meta‑analysis

Contact Info

Product

Resources

About